Volume 6.30 | Aug 14

Prostate Cell News 6.30 August 14, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
PIAS1 Is a Determinant of Poor Survival and Acts as a Positive Feedback Regulator of AR Signaling through Enhanced AR Stabilization in Prostate Cancer
Investigators addressed the question of whether protein inhibitor of activated signal transducer and activator of transcription-1 (PIAS1) targeting can be used as a basis for an improved prostate cancer therapy in combination with anti-androgens. [Oncogene] Full Article
Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
PUBLICATIONS (Ranked by impact factor of the journal)

Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade
Scientists showed that p62 is phosphorylated via a cascade that includes MEK3/6 and p38δ and is driven by the PB1-containing kinase MEKK3. Genetic inactivation of MEKK3 or p38δ mimics that of p62 in that it leads to inhibited growth of PTEN-deficient prostate organoids. [Cell Rep]
Full Article | Graphical Abstract | Press Release

Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveals Glycoprotein Alteration in Protein Abundance and Glycosylation
LNCaP and PC3 are prostate cancer cell lines that have been used as models for androgen-dependent and androgen-independent cell lines. Researchers report the analysis between these two prostate cancer cell lines using integrated global proteomics and glycoproteomics. [Mol Cell Proteomics] Abstract | Full Article

STIM1 Accelerates Cell Senescence in a Remodeled Microenvironment but Enhances the Epithelial-to-Mesenchymal Transition in Prostate Cancer
Researchers report an unexpected dual function of store-operated Ca2+ entry in prostate cancer progression by revealing a decrease in the expression of stromal interaction molecule 1 (STIM1) in human hyperplasia and tumor tissues of high histological grade and by demonstrating that STIM1 and ORAI1 inhibit cell growth by arresting the G0/G1 phase and enhancing cell senescence in human prostate cancer cells. [Sci Rep] Full Article

Syndecan-1 Up-Regulates MicroRNA-331-3p and Mediates Epithelial-to-Mesenchymal Transition in Prostate Cancer
Investigators identified neuropilin 2 and nucleus accumbens-associated protein 1 as putative target molecules in silico, as they were closely associated with the expression of microRNA-331-3p and TGF-β/Smad 4 signals. [Mol Carcinog] Abstract

ErbB-2 Signaling Plays a Critical Role in Regulating Androgen-Sensitive and Castration-Resistant Androgen Receptor-Positive Prostate Cancer Cells
Researchers determined the role of human epidermal growth factor receptor 2 (ErbB-2) in prostate cancer (PCa) progression and survival under steroid-reduced conditions using two independent PCa cell progression models. [Cell Signal] Abstract

Two Splice Variants of Y Chromosome-Located Lysine-Specific Demethylase 5D Have Distinct Function in Prostate Cancer Cell Line (DU-145)
Investigators detected two novel splice variants of lysine-specific demethylase 5D with lengths of 2650bp and 2400bp that correspond to the 100 and 80 kDa proteins in the human prostate cancer cell line, DU-145. [J Proteome Res] Abstract | Graphical Abstract

Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance
Human prostate cancer cell lines were evaluated for programmed death ligand-1 (PD-L1) expression and loss of phosphatase and tensin homolog (PTEN) by flow cytometry and western blotting, respectively. Immunohistochemical (IHC) staining for PTEN was correlated with PD-L1 IHC using a series of resected human prostate cancer samples. [Prostate Cancer Prostatic Dis] Abstract


Association between Very Small Tumor Size and Increased Cancer-Specific Mortality following Radical Prostatectomy in Node-Positive Prostate Cancer
Investigators aimed to determine whether very small prostate cancers present in patients who also have lymph node metastases represent a particularly aggressive disease variant compared to larger node-positive tumors. [BJU Int] Abstract

Urethra-Sparing High-Intensity Focused Ultrasound for Localized Prostate Cancer: Functional and Oncological Outcomes
Patients with negative findings in the urethra and the anterior urethral zone using transrectal ultrasound-guided targeted biopsies, and magnetic resonance imaging, received urethra-sparing or whole-gland high-intensity focused ultrasound as the primary therapy for localized prostate cancer without transurethral resection of the prostate. [Int J Urol] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
Stem Cells as Hormone Targets that Lead to Increased Cancer Susceptibility
Using the prostate gland as a model system, the authors highlight recent data that find that estrogens and endocrine-disrupting chemicals can reprogram prostate stem and progenitor cell populations, leading to increased cancer susceptibility. [Endocrinology] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Cancer Research Institute to Honor Outstanding Contributions to Basic and Tumor Immunology Research
The Cancer Research Institute will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy. [Cancer Research Institute] Press Release

Myriad Receives Favorable Medicare Final Coverage Decision for the Prolaris® Test
Myriad Genetics, Inc. announced that Noridian, the Medicare Administrative Contractor for Myriad, has issued a final local coverage determination for Prolaris®, Myriad’s pioneering prognostic test for assessing the aggressiveness of prostate cancer. [Myriad Genetics, Inc.] Press Release

Merck and MD Anderson Announce Immuno-Oncology Research Collaboration in Solid Tumors
Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA®, in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines. [The University of Texas MD Anderson Cancer Center] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Targeting Cell Death Mechanisms for the Treatment of Human Diseases
November 9-13, 2015
Suzhou, China

Visit our events page to see a complete list of events in the prostate cell community.
NEW Staff Scientist – Cancer Modeling (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Associate – Cancer Biology (Cornell University)

Research Associate – Prostate Cancer (Imperial College London)

Harry Eagle Scholar Awards for Postdoctoral Candidates (Albert Einstein College of Medicine of Yeshiva University)

Postdoctoral Positions – Cancer Research (Rutgers University)

Postdoctoral Position – Functional Cancer Genomics (Institute of Oncology Research)

Assistant Professor- Urology (University of California, Los Angeles)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us